Early Natural Killer Cell Reconstitution Predicts Overall Survival in T Cell-Replete Allogeneic Hematopoietic Stem Cell Transplantation.

[1]  E. Bandrés,et al.  The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients , 2015, Cellular and Molecular Life Sciences.

[2]  A. Tosti,et al.  Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality. , 2015, Blood.

[3]  J. Ritz,et al.  Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  S. Pittaluga,et al.  Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. , 2015, Blood.

[5]  M. Rehli,et al.  Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects , 2015, Oncoimmunology.

[6]  J. Partanen,et al.  Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients , 2014, Front. Immunol..

[7]  H. Einsele,et al.  Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Robin,et al.  Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation , 2014, Haematologica.

[9]  W. Scheper,et al.  Hunting for clinical translation with innate-like immune cells and their receptors , 2014, Leukemia.

[10]  A. Moretta,et al.  Human NK cell response to pathogens. , 2014, Seminars in immunology.

[11]  F. Locatelli,et al.  Natural killer cells in the treatment of high-risk acute leukaemia. , 2014, Seminars in immunology.

[12]  M. Adib-Conquy,et al.  TLR‐mediated activation of NK cells and their role in bacterial/viral immune responses in mammals , 2014, Immunology and cell biology.

[13]  S. Rutella,et al.  At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies , 2013, Journal of leukocyte biology.

[14]  L. Moretta,et al.  At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high‐risk leukemias , 2013, Journal of leukocyte biology.

[15]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[16]  J. Storek,et al.  Immune reconstitution after hematopoietic cell transplantation , 2012, Current opinion in hematology.

[17]  W. Hogan,et al.  Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  A. Gratwohl,et al.  Lymphocyte subset recovery and outcome after T-cell replete allogeneic hematopoietic SCT , 2011, Bone Marrow Transplantation.

[19]  R. Storb,et al.  Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. , 2011, Blood.

[20]  I. Kerridge,et al.  Pre‐transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[21]  H. Ljunggren,et al.  NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. , 2010, Blood.

[22]  H. Ulmer,et al.  The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  P. Ljungman,et al.  Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  R. Negrin,et al.  Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  J. Schold,et al.  The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease , 2008, Haematologica.

[26]  Marcela R. Uribe,et al.  Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia , 2007, Leukemia.

[27]  K. Rezvani,et al.  Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  G. Gastl,et al.  Impact of natural killer cell dose and donor killer‐cell immunoglobulin‐like receptor (KIR) genotype on outcome following human leucocyte antigen‐identical haematopoietic stem cell transplantation , 2007, Clinical and experimental immunology.

[29]  N. Lee,et al.  Rapid helper T-cell recovery above 200 × 106/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation , 2006, Bone Marrow Transplantation.

[30]  Edward A Copelan,et al.  Hematopoietic stem-cell transplantation. , 2006, The New England journal of medicine.

[31]  M. Horowitz,et al.  Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. , 2005, Blood.

[32]  M. Caligiuri,et al.  The biology of human natural killer-cell subsets. , 2001, Trends in immunology.

[33]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[34]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[35]  M. Martelli,et al.  NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. , 2008, Blood cells, molecules & diseases.